In the hope of resolving the apparently contradictory data for the effects of CXCR4/CXCL12 modulation in models of hepatic injury and evaluating whether CXCR4/CXCL12 could be a potential therapeutic target in fibrotic diseases, we tested the efficacy of AMD070 in a BLM induced murine model of PF and in a carbon tetrachloride (CCl4) induced murine model of hepatic fibrosis. Here, CXCL12 is linked to Hepatic fibrosis.